$SNY Income Statement | Understand Stock

$SNY

$41.79 +$0.19 (0.46%) Close

Financial Statements

In millions of EUR; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Net sales
Other revenues
Cost of sales
Gross profit
Research and development expenses
Selling and general expenses
Other operating income
Other operating expenses
Amortization of intangible assets
Impairment of intangible assets
Fair value remeasurement of contingent consideration
Restructuring costs and similar items
Other gains and losses, and litigation
Operating income
Financial expenses
Financial income
Income before tax and investments accounted for using the equity method
Income tax expense
Share of profit/(loss) from investments accounted for using the equity method
Net income from continuing operations
Net income excluding the exchanged/held-for-exchange Animal Health business
Net income
Net income attributable to non-controlling interests
Net income attributable to equity holders of Sanofi
Average number of shares outstanding (in shares)
Average number of shares after dilution (in shares)
Basic earnings per share excluding the exchanged/held-for-exchange Animal Health business (in euros per share)
Diluted earnings per share (in euros per share)
Basic earnings (loss) per share from discontinued operations
Basic earnings (loss) per share
Diluted earnings (loss) per share from discontinued operations
Diluted earnings (loss) per share

Comments